A challenge that we encountered in the present study was the following: the two methods used to inhibit PC1 activity, PC1 knockdown with siRNA and PC1 inhibition with IgPKD1, did not generate the same results for most cancer cell lines as far as Jak pathway activity is concerned. This evidence concerns the gene PKD1 and cancer.